Demeetra | Cell Line Development from Edit to Expression

Demeetra empowers biomanufacturers and researchers to move rapidly from precise gene edits to high-yield expression using a suite of proprietary, commercially accessible technologies. Our solutions optimize cell line development while eliminating common licensing and scalability barriers.

Our Technologies:

• Cas-CLOVER™: A high-fidelity nuclease that delivers clean, efficient gene knockouts and targeted knock-ins, with performance that rivals or exceeds CRISPR/Cas9.
• Harbor-IN™: A license-free transposase that enables stable integration of large genetic payloads, achieving high titers without royalties or downstream fees.
• CleanCut™ Host Cell Portfolio: Features a suspension CHO GS knockout line and an expanding collection of pre-engineered cell lines optimized for productivity and feature flexibility, accelerating your path to milestone success.

Why Demeetra:

• Editing Efficiency Meets Business Clarity: From superior editing precision to simplified licensing models, we remove the barriers that slow scientific and commercial progress.
• Clear Freedom to Operate: Straightforward licensing backed by issued patents and strategic foundational CRISPR/Cas9 agreements.
• No Royalties or Milestone Fees: Keep your autonomy with zero downstream restrictions or sublicensing complications.
• Enhanced Performance: Achieve larger knock-ins, higher expression yields, and cleaner edits than traditional Cas9 or other transposase systems.

Whether you’re advancing research or scaling a biotherapeutic pipeline, Demeetra equips your team with the tools and freedom to move forward faster and with confidence.